Articles tagged with Sars Cov 2
Researchers analyzed lung tissue from a COVID-19 patient to investigate histopathologic changes and SARS-CoV-2 immunostaining. The study found distinct patterns of immune cell activation and inflammation, shedding light on the disease's pathophysiology.
Researchers used existing data from known coronaviruses to predict which parts of SARS-CoV-2 are capable of activating the human immune system. The study identified five regions in the spike glycoprotein, membrane protein, and nucleoprotein that elicit a strong immune response.
Researchers estimate the median incubation period of COVID-19 to be 5.1 days, with 97.5% of cases developing symptoms within 11.5 days of infection. This supports current CDC recommendations for active monitoring and quarantine.
Researchers found that SARS-CoV-2 requires the protease TMPRSS2 to enter host cells, a target for therapeutic intervention. The drug camostat mesilate, approved for pancreatic inflammation, shows promise in blocking virus entry into lung cells.
A team of HKUST scientists has identified potential vaccine targets for SARS-CoV-2, leveraging genetic similarity with SARS-CoV. The study found that only 20% of SARS-CoV epitopes map identically to SARS-CoV-2, but these promising candidates may offer protection against COVID-19.
Four research teams at Columbia University will pursue four different approaches to develop drugs and antibodies against the new coronavirus. They aim to identify protease inhibitors, polymerase inhibitors, and monoclonal antibodies, with the goal of advancing at least one compound into clinical trials within a year.
Researchers describe key chest CT imaging findings in Wuhan coronavirus patients, highlighting bilateral ground-glass and consolidative pulmonary opacities. The study's findings suggest that lung cavitation, discrete nodules, and lymphadenopathy are characteristically absent in cases of 2019-nCoV.
A new modelling study estimates that up to 75,800 individuals in Wuhan may have been infected with 2019-nCoV by January 25, 2020. The researchers also suggest that multiple major Chinese cities might have already imported dozens of cases of 2019-nCoV infection from Wuhan.
The 2019-nCoV virus has nearly identical genetic sequences among patients, indicating a recent emergence and rapid detection. The virus shares similarities with bat-derived coronaviruses and may use the ACE2 receptor to enter human cells.
The Lancet report provides comprehensive clinical and treatment data on 2019-nCoV cases from Wuhan, China. Most patients had underlying chronic diseases and pneumonia, but responded well to antivirals and antibiotics.
The emergence of a new coronavirus from animals to humans poses a significant threat, prompting the need for swift action. Researchers are developing diagnostic tests, exploring broad-spectrum anti-viral drugs, and adapting approaches used with earlier outbreaks to jumpstart candidate vaccine development.
A new study reveals that the 2019-nCoV coronavirus likely originated from a combination of a bat coronavirus and an unknown coronavirus, with recombination allowing cross-species transmission to humans via snakes. This finding highlights the importance of understanding viral origins for effective control of emerging outbreaks.